Nektar Therapeutics

NKTR
Delayed Nasdaq - 11/21 10:00:00 pm
20.115USD
+0.93%
Prev.19.9300
Open19.8200
High20.4750
Low19.2700
Volume3 250 540
Financials
Sales 2019 108 M
EBIT 2019 -449 M
Net income 2019 -447 M
Finance 2019 234 M
Yield 2019 -
P/E ratio 2019 -7,81x
P/E ratio 2020 -8,08x
EV / Sales2019 30,3x
EV / Sales2020 18,0x
Capitalization 3 506 M
Company
Nektar Therapeutics specializes in the research and development of drugs for the treatment of cancer, autoimmune diseases and chronic pain. Net sales break down by source of income as follows:
- revenues from licensing and collaboration agreements (91.9%);
- product sales (4.6%);
- royalties...
Sector :
Biotechnology & Medical Research - NEC
Calendar :
2019-11-21 Presentation
Trading Rating :
Investor Rating :
Latest news
11/19NEKTAR THERAPEUTICS : Change in Directors or Principal Officers (form 8-K)
AQ
11/13NEKTAR THERAPEUTICS : to Webcast Presentation at Jefferies 2019 London Healthcare Conference
PR
11/09NEKTAR THERAPEUTICS : Presents New Clinical and Preclinical Data from its Immuno-Oncology Pipeline at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting
PR
11/07NEKTAR THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
11/06NEKTAR : 3Q Earnings Snapshot
AQ
11/06NEKTAR THERAPEUTICS : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)
AQ
11/01NEKTAR THERAPEUTICS : to Host Webcast Conference Call with Melanoma Specialist for Analysts & Investors During 2019 Society for Immunotherapy of Cancer 34th Annual Meeting
PR
10/30NEKTAR THERAPEUTICS : to Announce Financial Results for the Third Quarter 2019 on Wednesday, November 6, 2019, After Close of U.S.-Based Financial Markets
PR
Technical analysis trends
Short TermMid-TermLong Term
TrendBullishBearishBearish
Resistance21,024,628,0
Spread/Res.-4,1%-18%-28%
Spread/Supp.13%27%21%
Support17,815,916,7